Nanotech Investing Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Nanotech Investing Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
Nanotech Investing Silo Pharma Acquires ResearchCoin Crypto Tokens in Support of Decentralized Science
Nanotech Investing Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nanotech Investing Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nanotech Investing Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
Nanotech Investing Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
Nanotech Investing Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
Nanotech Investing Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
Nanotech Investing Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
Nanotech Investing Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
Nanotech Investing Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505 Pathway
